Replies to post #360 on Bottom Fish Stocks (between .10 and$10)

[King Stuki]

Hi Catfish,

Thanks for the quick reply.
I am in all four but not doing well.
Somehow I think it pays to hold SEHO.

For NEOP you may want to look at
http://www.investorshub.com/boards/board.asp?board_id=853
Dewdiligence and DrBio post the most and do not agree on NEOP's near term outlook. DrBio is bullish Dew thinks he is overly optimistic.

I have the same view of EMFP.

FRCP's sales are going up and they are adding production capacity. As you say, their PR sounds great and the product seems perfect for the times. I have a bit more shares of FRCP than I would like.


You guys may want to consider GENR at about $4.pps with a long term view. It seems to have the best approach to wet macular degeneration, a quite big market. It could also jump quickly if they announce a partnership with big pharma. I would watch it a bit as the price has been rising lately. I think this is in anticapation of ASCO, which begins this Saturday. I think GENR is not serious about cancer so I don't think any thing great will come out. The price may fall after. Just my opinion.
There is a terrific sight to investigate GENR if you are interested.
http://www.investorshub.com/boards/board.asp?board_id=1418

Thanks,

Stuki

[leagle]

SEHO-new financing, new business with patent, has found a botto and should fly soon.

EMFP - just got FDA approval for export to China and elsewhere. This is going to surprise.

NEOP - still seems a bit expensive and the chart is pointing towards resistance in the .20's.

FRCP - don't follow too many shares.